TPST Tempest Therapeutics
Price Chart
Executive Summary
Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the exercise price on 1.17M existing warrants from $3.50 to $1.73 per share, plus issuing new short-term warrants for up to 2.34M additional shares at $1.73. The transaction provides near-term cash but adds significant potential dilution (up to ~3.5M new shares vs. current market cap of $26M), and the new warrants require stockholder approval before exercisability.
Key Financial Metrics
Actionable Insight
The warrant restructuring provides near-term cash but at the cost of substantial dilution and a lower effective strike price, signaling financial strain. Monitor stockholder vote on new warrant shares and any subsequent cash burn updates. The ~$2M raise is modest for a clinical-stage biotech; further capital needs are likely.
Key Facts
- Definitive agreement to exercise 1,172,414 existing warrants at reduced exercise price of $1.73/share (original $3.50), generating ~$2M gross proceeds.
- Company will issue new unregistered short-term warrants to purchase up to 2,344,828 shares at $1.73, exercisable upon stockholder approval and expiring 2 years from issuance.
- Potential additional gross proceeds of ~$4M if new warrants are fully exercised on a cash basis.
- H.C. Wainwright acting as exclusive placement agent.
- Proceeds used for working capital and general corporate purposes.
- Current market cap is $26M; total potential dilution from both warrant tranches is ~3.5M shares (significant relative to current float).
Financial Impact
Immediate ~$2M gross proceeds from existing warrant exercise; potential ~$4M additional from new warrants; total potential dilution of ~3.5M shares against $26M market cap.
Risk Factors
- Stockholder approval may not be obtained for new warrant shares, limiting upside from that tranche.
- Dilution from up to 3.5M new shares could pressure stock price.
- Company remains a clinical-stage biotech with no approved products; cash runway extension is limited.
- Forward-looking statements highlight going-concern risk and need for additional capital.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303540 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
8-K
| $1.45 $1.27 | ▼ −12.41% | ▼ −9.66% | $1.26 (−13.10%) |
|
May 29, 2026
15d ago
|
Press Release
| $1.53 $1.27 | ▲ +16.99% | ▲ +16.70% | $1.26 (+17.65%) |
|
May 22, 2026
21d ago
|
8-K
| $1.77 $1.31 | ▲ +25.99% | ▲ +27.20% | $1.26 (+28.81%) |
|
May 22, 2026
21d ago
|
8-K
| $1.77 $1.31 | ▲ +25.99% | ▲ +27.20% | $1.26 (+28.81%) |
|
May 14, 2026
29d ago
|
8-K
| $1.83 $1.86 | ▼ −1.64% | ▼ −0.68% | $1.26 (+31.15%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $1.74 $2.15 | ▲ +23.56% | ▲ +20.45% | $1.26 (−27.59%) |
|
Apr 6, 2026
9w ago
|
EFFECT
| $1.59 $2.14 | ▲ +34.59% | ▲ +30.46% | $1.26 (−20.75%) |
|
Apr 2, 2026
10w ago
|
S-3
| $1.59 $2.05 | ▲ +28.93% | ▲ +25.31% | $1.26 (−20.75%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.52 $1.56 | ▲ +2.63% | ▼ −1.67% | $1.26 (−17.11%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $2.40 $2.16 | ▼ −10.00% | ▼ −7.81% | $1.26 (−47.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access